The European Medicines Agency has approved the biopharmaceutical company Springworks' drug for treating fibrous dysplasia.

On June 20, at the meeting of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, positive opinions were given for Springworks' drug Ogsiveo for the treatment of adult patients with progressive desmoid tumors.